Drugs / Zuclopenthixol

Trials 4

20132014201520162017201820192020202120222023202420252026202720282029203020312032
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 21 trial
Phase 2 NCT07152184 Oct 2026 → Feb 2032 expected schizophrenia University Hospital, Strasbourg, France Not yet recruiting No outcome recorded
Phase 32 trials
Phase 3 NCT02374567 Jan 2015 → Jun 2017 anxiety disorder, dementia, depressive disorder, schizophrenia +1 Hannover Medical School Terminated No outcome recorded
Phase 3 NCT01765829 Nov 2012 → Nov 2015 psychotic disorder Fundación Pública Andaluza Progreso y Salud Unknown No outcome recorded
Phase 41 trial
Phase 4 NCT02307396 Feb 2015 → Jun 2016 schizoaffective disorder, schizophrenia Technical University of Munich Completed No outcome recorded
Comparator or background therapy3 trials
Phase 2 NCT01323205 Background May 2011 → Nov 2012 schizophrenia Janssen Research & Development, LLC Completed No outcome recorded
Phase 4 NCT07047651 Background Jun 2025 → Dec 2027 expected treatment-refractory schizophrenia Dr. Stavroula Rakitzi Active not recruiting No outcome recorded
— NCT00206960 Comparator Jan 1998 → Sep 2010 schizophrenia Birte Glenthoj Completed No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 7 sources stand behind the page.

FieldValueCited text
Known as zuclopenthixol “Drugs: Aripiprazole, Olanzapine, Zuclopenthixol, Clotiapine, Flupentixol, Risperidone, Sulpiride, Trifluoperazine, Haloperidol, Quetiapine, Paliperidone, Chlorpromazine,...” NCT01765829 ↗
4

NCT00206960 ↗

NCT02374567 ↗

NCT02307396 ↗

NCT07152184 ↗

Known as clopixol ClinicalTrials.gov intervention name — accepted as the source's own label NCT07047651 ↗
Known as Zuclopenthixol Hydrochloride “Regular antipsychotic medications (Risperidone, Olanzapine, Clozapine, Amisulpride, Quetiapine, Paliperidone, Aripiprazole, Haloperidol, Levomepromazine, Zuclopenthixol...” NCT01323205 ↗
Route Oral “administered zuclopenthixol orally” NCT00206960 ↗